Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.

Cancers (Basel) · 2022 · PMC9324890 · PMID 35884448

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

No significant difference in DFS was found between thymic carcinoma patients with and without pathogenic SNVs ( p = 0.190); however, the latter showed a trend towards a longer median DFS (16.0 vs. 30.0 months, respectively; Figure 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in <i>KIT</i>, <i>ERBB2</i>, <i>KRAS</i>, and <i>TP53</i> in 30% of Thymic Carcinomas.

The sentences